Diamyd Medical is engaged in discussions regarding an extension of GABA/Diamyd® trial in Birmingham, Alabama

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced in its second quarterly report for the fiscal year 2015/2016 that the Company is engaged in discussions regarding an extension of the ongoing GABA/Diamyd®-trial in Birmingham, Alabama. The Company also announced that the associated company Companion Medical, Inc. has submitted a 510(k) Premarket Notification in the US as well as a CE-mark application in Europe.Moreover, the CEO’s comments in today’s quarterly report reads as follows. The second quarter of this fiscal year and the period thereafter have been